(Q45858520)

English

Mucosal immunization against hepatitis A: antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid

scientific article published on 2 May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

Mucosal immunization against hepatitis A: antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Leslie Ann Mitchell

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

Aviva Joseph

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

Eli Kedar

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

Yechezkel Barenholz

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

Eitan Galun

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

language of work or name

0 references

publication date

2 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

24

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

25

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

5300-5310

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

Prevention of hepatitis A with the hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Adult infection with hepatitis A despite declining endemicity; in favor of adult vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Emergency response vaccines--a challenge for the public sector and the vaccine industry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Mucosal immune network in the gut for the control of infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Rectal immunization of mice with hepatitis A vaccine induces stronger systemic and local immune responses than parenteral immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Immunostimulatory DNA is a potent mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

A Toll-like receptor recognizes bacterial DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.015

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.04.015

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/16714070

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45858520&oldid=2086751701"